GLP-1 Agonist Prescriptions Soar Among Non-Diabetic Medicare Beneficiaries
Background
Glucagon-Like Peptide 1 (GLP-1) agonists, a class of drugs that mimic a natural hormone to regulate blood sugar and appetite, are primarily approved for managing type 2 diabetes and increasingly for obesity. While their use has surged globally, comprehensive data on their utilization among individuals without a diabetes diagnosis, particularly within the Medicare Part D population, has been limited. This study aimed to quantify the prevalence, characteristics, and trends of GLP-1 agonist prescriptions for non-diabetic Medicare Part D enrollees.
Results
The study revealed a dramatic increase in GLP-1 agonist prescriptions for non-diabetic Medicare Part D beneficiaries. Between 2018 and 2023, there was a 350% increase in these prescriptions, reaching over 1.2 million prescriptions annually by the end of the study period. Semaglutide, including both Ozempic and Wegovy formulations, emerged as the dominant GLP-1 agonist, accounting for 78% of all prescriptions in this non-diabetic group by 2023. A substantial proportion, approximately 65%, of these non-diabetic users had an obesity diagnosis (BMI > 30 kg/m²), indicating significant off-label use for weight management before specific obesity indications were widely covered. The average age of non-diabetic GLP-1 users was 68.5 years, with 62% being female. The most significant finding was a 350% increase in GLP-1 agonist prescriptions for non-diabetic Medicare Part D beneficiaries between 2018 and 2023, reaching over 1.2 million prescriptions annually.
Why It Matters
This study highlights a significant and rapid shift in GLP-1 agonist utilization patterns, extending well beyond their primary indication for type 2 diabetes into the non-diabetic population. The substantial increase in prescriptions, particularly for obesity management, underscores the growing demand for effective weight loss therapies among older adults. Understanding these real-world prescribing trends is crucial for policymakers, healthcare providers, and insurers to ensure appropriate access, manage escalating costs, and develop informed guidelines for GLP-1 use in diverse populations. Future research should focus on assessing the long-term clinical outcomes, safety profiles, and cost-effectiveness of GLP-1 agonists in this non-diabetic cohort to inform future coverage decisions and potential broader indications.